Core Insights - Knight Therapeutics Inc. has relaunched ORGOVYX (relugolix) in Canada, marking a significant step in its oncology portfolio [1][4] - ORGOVYX is the first oral GnRH receptor antagonist approved in Canada for advanced prostate cancer treatment, with a market valued at over $200 million and a five-year CAGR of 8% [3][5] Company Overview - Knight Therapeutics Inc. is a specialty pharmaceutical company focused on acquiring and commercializing pharmaceutical products in Canada and Latin America [7] - The company has entered into exclusive license and supply agreements with Sumitomo Pharma America Inc. for multiple products, including ORGOVYX [2] Product Details - ORGOVYX (relugolix) is designed to provide a convenient oral alternative for rapidly suppressing testosterone production in prostate cancer patients [4] - Sales of ORGOVYX in Canada were approximately $1.2 million in 2024 [5] Market Context - Prostate cancer is the most prevalent malignancy among Canadian men, with an estimated 24,700 diagnoses and approximately 4,700 deaths in 2023 [6] - The treatment landscape for prostate cancer includes both GnRH agonists and antagonists, with ORGOVYX positioned to compete effectively in this market [3]